These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent EZH2 inhibitors for the treatment of B-cell lymphomas. Wu D; Zeng X; Zhao Y; Qin M; Gong P Bioorg Med Chem; 2024 May; 105():117725. PubMed ID: 38640588 [TBL] [Abstract][Full Text] [Related]
3. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors. Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and activity evaluation of quinolinone derivatives as EZH2 inhibitors. Cai J; You H; Qin X; Wang Y; Li W Bioorg Med Chem Lett; 2024 Jun; 105():129726. PubMed ID: 38580135 [TBL] [Abstract][Full Text] [Related]
5. Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas. Zhou B; Liang X; Mei H; Qi S; Jiang Z; Wang A; Zou F; Liu Q; Liu J; Wang W; Hu C; Chen Y; Wang Z; Wang B; Wang L; Liu J; Liu Q J Med Chem; 2021 Oct; 64(20):15170-15188. PubMed ID: 34664960 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of benzimidazole derivatives as novel human Pin1 inhibitors. Ma T; Huang M; Li A; Zhao F; Li D; Liu D; Zhao L Bioorg Med Chem Lett; 2019 Jul; 29(14):1859-1863. PubMed ID: 31103446 [TBL] [Abstract][Full Text] [Related]
7. Identification of novel EZH2 inhibitors through pharmacophore-based virtual screening and biological assays. Wu Y; Hu J; Ding H; Chen L; Zhang Y; Liu R; Xu P; Du D; Lu W; Liu J; Liu Y; Liu YC; Lu J; Zhang J; Yao Z; Luo C Bioorg Med Chem Lett; 2016 Aug; 26(15):3813-7. PubMed ID: 27289323 [TBL] [Abstract][Full Text] [Related]
8. Methotrexate and Curcumin co-encapsulated PLGA nanoparticles as a potential breast cancer therapeutic system: In vitro and in vivo evaluation. Vakilinezhad MA; Amini A; Dara T; Alipour S Colloids Surf B Biointerfaces; 2019 Dec; 184():110515. PubMed ID: 31585308 [TBL] [Abstract][Full Text] [Related]
9. Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction. Du D; Xu D; Zhu L; Stazi G; Zwergel C; Liu Y; Luo Z; Li Y; Zhang Y; Zhu K; Ding Y; Liu J; Fan S; Zhao K; Zhang N; Kong X; Jiang H; Chen K; Zhao K; Valente S; Min J; Duan W; Luo C J Med Chem; 2021 Jun; 64(12):8194-8207. PubMed ID: 34077206 [TBL] [Abstract][Full Text] [Related]
10. Discovery, design, and synthesis of indole-based EZH2 inhibitors. Gehling VS; Vaswani RG; Nasveschuk CG; Duplessis M; Iyer P; Balasubramanian S; Zhao F; Good AC; Campbell R; Lee C; Dakin LA; Cook AS; Gagnon A; Harmange JC; Audia JE; Cummings RT; Normant E; Trojer P; Albrecht BK Bioorg Med Chem Lett; 2015 Sep; 25(17):3644-9. PubMed ID: 26189078 [TBL] [Abstract][Full Text] [Related]
11. Identification of novel EED-EZH2 PPI inhibitors using an in silico fragment mapping method. Misawa K; Yamaotsu N; Hirono S J Comput Aided Mol Des; 2021 May; 35(5):601-611. PubMed ID: 33635506 [TBL] [Abstract][Full Text] [Related]
12. Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer. Li X; Gera L; Zhang S; Chen Y; Lou L; Wilson LM; Xie ZR; Sautto G; Liu D; Danaher A; Mamouni K; Yang Y; Du Y; Fu H; Kucuk O; Osunkoya AO; Zhou J; Wu D Theranostics; 2021; 11(14):6873-6890. PubMed ID: 34093859 [No Abstract] [Full Text] [Related]
13. Design and synthesis of (E)-1,2-diphenylethene-based EZH2 inhibitors. He H; Hu X; Teng F; Liu Z; Zhang Q; Feng Z; Feng Q; Yu L Bioorg Med Chem Lett; 2020 Mar; 30(5):126957. PubMed ID: 31959420 [TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-Fluorouracil and perfluorocarbon. Wu P; Zhou Q; Zhu H; Zhuang Y; Bao J BMC Cancer; 2020 Apr; 20(1):354. PubMed ID: 32345258 [TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma. Tu Y; Sun Y; Qiao S; Luo Y; Liu P; Jiang ZX; Hu Y; Wang Z; Huang P; Wen S J Med Chem; 2021 Jul; 64(14):10167-10184. PubMed ID: 34196564 [TBL] [Abstract][Full Text] [Related]
16. Covalent inhibitors of EZH2: Design, synthesis and evaluation. Zhang Q; Chen X; Hu X; Duan X; Wan G; Li L; Feng Q; Zhang Y; Wang N; Yu L Biomed Pharmacother; 2022 Mar; 147():112617. PubMed ID: 34998031 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of benzomorpholine derivatives as novel EZH2 inhibitors for anti-non-small cell lung cancer activity. Feng Q; He H; Gao T; Zhang Q; Liu Z; Tao X; Zhu Y; Zhang L; Yu L Mol Divers; 2019 Aug; 23(3):681-696. PubMed ID: 30612258 [TBL] [Abstract][Full Text] [Related]
18. Poly-(Lactic-co-Glycolic) Acid Nanoparticles for Synergistic Delivery of Epirubicin and Paclitaxel to Human Lung Cancer Cells. Sharma N; Kumari RM; Gupta N; Syed A; Bahkali AH; Nimesh S Molecules; 2020 Sep; 25(18):. PubMed ID: 32947799 [TBL] [Abstract][Full Text] [Related]
19. Chemically induced degradation of PRC2 complex by EZH2-Targeted PROTACs via a Ubiquitin-Proteasome pathway. Fu M; Wang Y; Ge M; Hu C; Xiao Y; Ma Y; Gou S Bioorg Med Chem Lett; 2024 Nov; 113():129968. PubMed ID: 39293534 [TBL] [Abstract][Full Text] [Related]
20. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor. Honma D; Kanno O; Watanabe J; Kinoshita J; Hirasawa M; Nosaka E; Shiroishi M; Takizawa T; Yasumatsu I; Horiuchi T; Nakao A; Suzuki K; Yamasaki T; Nakajima K; Hayakawa M; Yamazaki T; Yadav AS; Adachi N Cancer Sci; 2017 Oct; 108(10):2069-2078. PubMed ID: 28741798 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]